Dihydrofolate Reductase I164L Mutation in Plasmodium falciparum, Madagascar by Ménard, Didier et al.
LETTERS
  2.   Kilpatrick  AM,  Chimura  AA,  Gibbons 
DW, Fleischer RC, Marra PP, Daszak P. 
Predicting the global spread of H5N1 
avian inﬂ  uenza. Proc Natl Acad Sci U S 
A. 2006;103:19368–73. DOI: 10.1073/
pnas.0609227103
  3.   Delany S, Scott D, eds. Waterbird popu-
lation estimates. 4th ed. Wageningen (the 
Netherlands): Wetlands International; 
2006.
  4.   Brown JD, Swayne DE, Cooper RJ, Burns 
RE, Stallknecht DE. Persistence of H5 
and H7 avian inﬂ  uenza viruses in water. 
Avian Dis. 2007;51(Suppl):285–9. DOI: 
10.1637/7636-042806R.1
  5.   Guillemain M, Fritz H, Klaassen M, John-
son AR, Hafner H. Fuelling rates of gar-
ganey (Anas querquedula) staging in the 
Camargue, southern France, during spring 
migration. J Ornithol. 2004;145:152–8. 
DOI: 10.1007/s10336-004-0026-9
  6.   Brown JD, Stallknecht DE, Beck JR, Su-
arez DL, Swayne DE. Susceptibility of 
North American ducks and gulls to H5N1 
highly pathogenic avian inﬂ  uenza viruses. 
Emerg Infect Dis. 2006;12:1663–70.
    7.    Weber TP, Stilianakis NI. Ecologic im-
munology of avian inﬂ  uenza  (H5N1) 
in migratory birds. Emerg Infect Dis. 
2007;13:1139–43.
  8.   Watch EMPRES. HPAI in Europe 2007: 
concurrent outbreaks in poultry and wild 
birds. Rome: Food and Agriculture Or-
ganization of the United Nations; 2007 
[cited 2007 Sep 12]. Available from www.
fao.org/docs/eims/upload/231765/EW_
Europe_aug07_ai.pdf
  9.   Saad  MD,  Ahmed  LS,  Gamal-Eldein 
MA, Fouda MK, Khalil FM, Yingst SL. 
Possible avian inﬂ   uenza (H5N1) from 
migratory bird, Egypt. Emerg Infect Dis. 
2007;13:1120–1.
10.   Chen H, Li KS, Wang J, Fan XH, Rayner 
JM, Vijaykrishna D, et al. Establish-
ment of multiple sublineages of H5N1 
inﬂ  uenza virus in Asia: Implications for 
pandemic control. Proc Natl Acad Sci U 
S A. 2006;103:2845–50. DOI: 10.1073/
pnas.0511120103
Address for correspondence: Nicolas Gaidet, 
Département Environnements et Sociétés, Centre 
de Coopération Internationale en Recherche 
Agronomique pour le Développement, UR 
Gestion Intégrée de la Faune TA 30/E Campus 
International de Baillarguet, 34398 Montpellier, 
France; email: nicolas.gaidet@cirad.fr
Dihydrofolate 
Reductase I164L 
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Plasmodium 
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Madagascar 
To the Editor: Malaria remains 
a major public health problem and a 
primary cause of illness in Madagas-
car (1). Since 2005, the National Ma-
laria Control Program has revised its 
treatment policy and replaced chlo-
roquine (CQ) with artesunate plus 
amodiaquine as ﬁ  rst-line therapy for 
uncomplicated malaria and CQ with 
sulfadoxine-pyrimethamine (SP) for 
prevention of malaria during pregnan-
cy. The latter choice was partially sup-
ported by high effectiveness of SP and 
absence of pyrimethamine resistance 
in Madagascar, in contrast to proximal 
African countries such as the Comoros 
Islands (2,3).
Analysis of the molecular basis 
of antimalarial drug resistance has 
demonstrated that mutations in the 
dihydrofolate reductase (dhfr) and 
dihydropteroate synthase genes are 
associated with development of SP 
resistance. It has been assumed that 
pyrimethamine resistance conferred 
by multiple mutations arose through 
stepwise selection of the S108N 
single mutant (except for the A16V/
S108T allele). This single-point muta-
tion decreases the sensitivity of dhfr 
to pyrimethamine in vitro by ≈10× 
(4). Subsequent mutations, such as 
N51I and C59R, cause additional de-
creases in the sensitivity of dhfr to py-
rimethamine. Parasites with a triple-
mutant allele (51I/59R/108N) are less 
sensitive to pyrimethamine in vitro, 
and patients infected with these para-
sites have a high probability of not re-
sponding to SP treatment (5).
Addition of I164L to 
51I/59R/108N creates a quadruple-
mutant allele and decreases the sensi-
tivity of dhfr by ≈1,000× (4), eliminat-
ing the clinical effectiveness of SP, as 
observed in Southeast Asia and South 
America. However, the situation in 
Africa seems to be different because 
most studies conducted since the mid 
1990s have shown the quadruple mu-
tant to be rare, even in areas of inten-
sive pyrimethamine use (6). Increasing 
SP resistance is principally a result of 
rapid selection for parasites that car-
ry a triple-mutant allele that arose in 
Southeast Asia and has spread widely 
in Africa (7,8).
In 2006, blood samples were ob-
tained from 114 children 6 months to 
15 years of age enrolled in a clinical 
trial monitoring the efﬁ  cacy of SP in 
treatment of uncomplicated Plasmodi-
um falciparum malaria. The dhfr gene 
from pretreatment samples was se-
quenced at the Genomics Platform of 
the Pasteur Institute in Paris, France. 
Four (3%) samples contained the 108N 
single-mutant allele, 37 (32%) con-
tained the 51I/59R/108N triple-mu-
tant allele, and 1 (<1%) contained the 
I164L single-mutant allele. This latter 
allele was obtained from the blood of 
a 15-year-old girl from Ejeda in south-
ern Madagascar. At enrollment in the 
trial, she had an axillary temperature 
of 37.8°C and a P. falciparum asexual 
parasite count of 74,880/μL. She was 
treated with the standard SP regimen 
(25 mg/kg sulfadoxine and 1.25 mg/kg 
pyrimethamine as a single dose on day 
0). On the basis of the World Health 
Organization 2003 protocol (9), early 
treatment failure was noted on day 2, 
when the patient had signs of malaria 
with a temperature of 40°C and a para-
site count of 770/μL. She was success-
fully retreated with a rescue regimen 
(quinine, 8 mg base/kg, 3 times a day 
for 7 days). 
To conﬁ  rm detection of the I164L 
allele, parasite DNA was extracted 
from blood spots obtained on days 0, 1, 
and 2 and sequenced. DNA templates 
were sent to a second independent 
laboratory (Department of Genome 
Sciences, University of Washington, 
Seattle, WA, USA) to rule out misiden-
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tiﬁ  cation or polymerase errors. Nucle-
otide sequences obtained were com-
pared with wild-type sequence (isolate 
3D7, pyrimethamine-sensitive, Gen-
Bank accession no. NC_004318.1) by 
using BioEdit software (www.mbio.
ncsu.edu/BioEdit/BioEdit.html). No 
point mutations other than I164L were 
observed in any samples obtained on 
3 consecutive days. The nucleotide 
sequence determined in this study has 
been deposited in the GenBank data-
base (accession no. EU280750).
Our report provides new insights 
into development of antifolate-resis-
tant malaria and supports the ﬁ  ndings 
of McCollum et al. (10) that the muta-
tions in the dhfr gene do not always oc-
cur in a predictable, ordered, stepwise 
manner. Although the I164L allele was 
detected in a clinical sample from a pa-
tient who showed early treatment fail-
ure, blood levels of the drug were not 
measured. Thus, it is not possible to 
establish a causal connection between 
the I164L mutation and SP resistance. 
Moreover, the substantial reduction in 
parasite counts observed on days 0, 1, 
and 2 implied that SP treatment helped 
reduce parasite counts.
Our data conﬁ  rm that the I164L 
mutation is beginning to appear in Af-
rica. This observation highlights the 
risk for emergence and spread of the 
51I/59R/108N/164L quadruple-mu-
tant dhfr genotype by recombination 
between the I164L genotype and the 
51I/59R/108N triple-mutant genotype, 
which would make SP widely ineffec-
tive for intermittent treatment of ma-
laria during pregnancy. Further studies 
are needed to understand whether the 
I164L genotype has emerged in Mad-
agascar because of local evolutionary 
history or has been introduced by gene 
ﬂ  ow from India or Southeast Asia, and 
to evaluate the risk for spread of this 
genotype to the rest of Africa through 
Madagascar. 
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